AZITRA INC (AZTR) Stock Price & Overview
NYSEARCA:AZTR • US05479L3024
Current stock price
The current stock price of AZTR is 0.214 USD. Today AZTR is up by 0.19%. In the past month the price decreased by -21.98%. In the past year, price decreased by -89.89%.
AZTR Key Statistics
- Market Cap
- 3.465M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -2.25
- Dividend Yield
- N/A
AZTR Stock Performance
AZTR Stock Chart
AZTR Technical Analysis
ChartMill assigns a technical rating of 1 / 10 to AZTR. When comparing the yearly performance of all stocks, AZTR is a bad performer in the overall market: 96.62% of all stocks are doing better.
AZTR Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to AZTR. Both the profitability and financial health of AZTR have multiple concerns.
AZTR Earnings
AZTR Forecast & Estimates
7 analysts have analysed AZTR and the average price target is 1.38 USD. This implies a price increase of 543.46% is expected in the next year compared to the current price of 0.214.
AZTR Groups
Sector & Classification
AZTR Financial Highlights
Over the last trailing twelve months AZTR reported a non-GAAP Earnings per Share(EPS) of -2.25. The EPS increased by 85.76% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -218% | ||
| ROE | -288.21% | ||
| Debt/Equity | 0.05 |
AZTR Ownership
AZTR Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 13.52 | 362.808B | ||
| AMGN | AMGEN INC | 15.15 | 186.117B | ||
| GILD | GILEAD SCIENCES INC | 15.03 | 165.442B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 22.47 | 111.051B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.92 | 79.011B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 45.5 | 41.154B | ||
| INSM | INSMED INC | N/A | 30.431B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 29.508B | ||
| NTRA | NATERA INC | N/A | 29.114B | ||
| BIIB | BIOGEN INC | 11.79 | 27.29B | ||
| UTHR | UNITED THERAPEUTICS CORP | 19.65 | 25.135B | ||
| MRNA | MODERNA INC | N/A | 21.507B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 20.454B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the NYSE Arca Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About AZTR
Company Profile
Azitra, Inc. is an early-stage clinical biopharmaceutical company, which engages in the development of therapeutic use in dermatology. The company is headquartered in Branford, Connecticut and currently employs 13 full-time employees. The company went IPO on 2023-06-16. The firm is focused on developing advanced therapies for precision dermatology using engineered proteins and topical live biotherapeutic products. The company has built a proprietary platform that includes a microbial library comprised of approximately 1,500 unique bacterial strains that can be screened for therapeutic characteristics. The platform is augmented by artificial intelligence and machine learning technology that analyzes, predicts and helps screen its library of strains for drug-like molecules. Its lead product, ATR-12, is a genetically modified strain of S. epidermidis for treating the orphan disease, Netherton syndrome, a chronic and fatal disease of the skin. Its advanced product, ATR-04, is a genetically modified strain of S. epidermidis for treating papulopustular rash. Its product ATR-01 is a human filaggrin protein for treating ichthyosis vulgaris, a chronic, xerotic (abnormally dry), and scaly skin disease.
Company Info
IPO: 2023-06-16
AZITRA INC
21 Business Park Drive, Suite 6
Branford CONNECTICUT US
Employees: 13
Phone: 12034890183
AZITRA INC / AZTR FAQ
What does AZITRA INC do?
Azitra, Inc. is an early-stage clinical biopharmaceutical company, which engages in the development of therapeutic use in dermatology. The company is headquartered in Branford, Connecticut and currently employs 13 full-time employees. The company went IPO on 2023-06-16. The firm is focused on developing advanced therapies for precision dermatology using engineered proteins and topical live biotherapeutic products. The company has built a proprietary platform that includes a microbial library comprised of approximately 1,500 unique bacterial strains that can be screened for therapeutic characteristics. The platform is augmented by artificial intelligence and machine learning technology that analyzes, predicts and helps screen its library of strains for drug-like molecules. Its lead product, ATR-12, is a genetically modified strain of S. epidermidis for treating the orphan disease, Netherton syndrome, a chronic and fatal disease of the skin. Its advanced product, ATR-04, is a genetically modified strain of S. epidermidis for treating papulopustular rash. Its product ATR-01 is a human filaggrin protein for treating ichthyosis vulgaris, a chronic, xerotic (abnormally dry), and scaly skin disease.
What is the current price of AZTR stock?
The current stock price of AZTR is 0.214 USD. The price increased by 0.19% in the last trading session.
Does AZTR stock pay dividends?
AZTR does not pay a dividend.
What is the ChartMill rating of AZITRA INC stock?
AZTR has a ChartMill Technical rating of 1 out of 10 and a ChartMill Fundamental rating of 1 out of 10.
Can you provide the sector and industry classification for AZITRA INC?
AZITRA INC (AZTR) operates in the Health Care sector and the Biotechnology industry.
What is the market capitalization of AZTR stock?
AZITRA INC (AZTR) has a market capitalization of 3.46M USD. This makes AZTR a Nano Cap stock.